Document:

Exhibit 10.2

 

NABUFIT GLOBAL, INC.

COMMON STOCK SUBSCRIPTION AGREEMENT

The undersigned (the "Investor") hereby confirms its agreement with NABUfit Global, Inc., a Delaware corporation (the "Company") as follows:

1. This Subscription Agreement, including the Terms and Conditions for Purchase of Shares attached hereto as Annex I (collectively, (this "Agreement") is made as of the date set forth below between the Company and the Investor.

2. The Company has authorized the sale and issuance to certain investors of up to an aggregate of 5,000,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), of the Company (the "Shares"). The purchase price per Share shall be $0.92 (the "Share Purchase Price"). The Shares will be certificated and the Shares shall be immediately transferable upon issuance.

3. The offering and sale of the Shares (the "Offering") are being made pursuant to (1) an effective Registration Statement on Form S-1, File No. 333-210325 (including any additional registration statement or post-effective amendment filed with respect thereto pursuant to Rule 462(b) under the Shares Act (as defined below) the "Registration Statement") filed by the Company with the Shares and Exchange Commission (the "Commission") (including the prospectus contained therein (the "Prospectus") and (2) if applicable, certain "free writing prospectuses" (as that term is defined in Rule 405 under the Shares Act of 1933, as amended (the "Shares Act")), that have been or will be filed with the Commission and delivered to the Investor on or prior to the date hereof (the "Issuer Free Writing Prospectus"), containing certain supplemental information regarding the Shares, the terms of the Offering and the Company.

4. The Company and the Investor agree that the Investor will purchase from the Company and the Company will issue and sell to the Investor the Shares set forth below for the aggregate Purchase Price set forth below. The Shares shall be purchased pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex I and incorporated herein by this reference as if fully set forth herein. The Investor acknowledges that the Offering is not being underwritten by an underwriter or placement agent and that there is no minimum offering amount.

5. The Shares shall be settled as follows:

 A. Cash Settlement.  Investor shall pay to the Company via direct wire transfer, cash or other immediately available funds an amount equal to the aggregate purchase price for the Shares being purchased by the Investor to the following account designated by the Company:

[To be separately provided to the Investor.]

Upon receipt of the Purchase Price, the Company shall provide a copy of this Agreement to the Company's Transfer Agent with instructions to deliver a certificate representing the Shares ("Certificate") or electronically through DWAC to the investors account at the Investor's broker upon the broker requesting the Company's Transfer Agent that the shares be delivered electronically through DWAC.  The Investor may purchase the shares in one or more transactions for a period of three months from the date of this Agreement.

6. The Investor represents that, except as set forth below, (a) it has had no position, office or other material relationship within the past three years with the Company or persons known to it to be affiliates of the Company, (b) it is not a member of the Financial Industry Regulatory Authority, Inc. ("FINRA") or an Associated Person (as such term is defined under the FINRA's NASD Membership and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor nor any group of Investors (as identified in a public filing made with the Commission) of which the Investor is a part in connection with the Offering, acquired, or obtained the right to acquire, 20% or more of the Common Stock (or securities convertible into or exercisable for Common Stock) or the voting power of the Company on a post-transaction basis. Exceptions:

 a.  _________________________________________________   

b.  _________________________________________________   

 (If no exceptions, write "none." If left blank, response will be deemed to be "none.")

7. The Investor represents that it has received (or otherwise had made available to it by the filing by the Company of an electronic version thereof with the Commission) the Prospectus, filed June 6, 2016 which is a part of the Company's Registration Statement, the documents incorporated by reference therein and any free writing prospectus (collectively, the "Disclosure Package"), prior to or in connection with the receipt of this Agreement. The Investor acknowledges that, prior to the delivery of this Agreement to the Company, the Investor will receive certain additional information regarding the Offering, including pricing information (the "Offering Information"). Such information may be provided to the Investor by any means permitted under the Shares Act, including a free writing prospectus and oral communications.

8. No offer by the Investor to buy Shares will be accepted and no part of the Purchase Price will be delivered to the Company until the Investor has received the Offering Information and the Company has accepted such offer by countersigning a copy of this Agreement, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the Company sending (orally, in writing or by electronic mail) notice of its acceptance of such offer. An indication of interest will involve no obligation or commitment of any kind until the Investor has been delivered the Offering Information and this Agreement is accepted and countersigned by or on behalf of the Company.

9. The Company acknowledges that the only material, non-public information relating to the Company or its subsidiaries that the Company, its employees or agents has provided to the Investor in connection with the Offering prior to the date hereof are the material pricing terms of the Offering.

Number of Shares:

Purchase Price per Share: USD $0.92

Aggregate Purchase Price: USD $

[Signature Page Follows]

Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.

 

	 	Dated as of: 	______________, 2016 
	 	 	 
	
 

	INVESTOR	
 

	 	 	 	 
	
 

	
 

	
 

	
 

	
 

	
 

	
By:

	
 

	
 

	
 

	
Print Name:

	
 

	
 

	
 

	
Title:

	
 

	
 

	
 

	
Address:

	
 

	
 

	
 

	
 

	
 

 

	 	Agreed and Accepted  
	 	this: 	______________, 2016 
	 	 	 
	
 

	
 

	
NABUFIT GLOBAL, INC.

	
 

	
 

	
By:

	
 

	
 

	
 

	
Title:

	
 

	
 

	
 

	
 

	
 

ANNEX I

TERMS AND CONDITIONS FOR PURCHASE OF SECURITIES

1. Authorization and Sale of the Shares. Subject to the terms and conditions of this Agreement, the Company has authorized the sale of the Shares.

2. Agreement to Sell and Purchase the Shares;

2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor, and the Investor will purchase from the Company, upon the terms and conditions set forth herein, the number of Shares set forth on the last page of the Agreement to which these Terms and Conditions for Purchase of Shares are attached as Annex I (the "Signature Page") for the aggregate purchase price therefor set forth on the Signature Page.

2.2 The Company proposes to enter into substantially this same form of Subscription Agreement with certain other investors (or, alternatively, sell Shares pursuant to the Prospectus without any Subscription Agreement) (the "Other Investors") and expects to complete sales of Shares to them. The Investor and the Other Investors are hereinafter sometimes collectively referred to as the "Investors," and this Agreement and the Subscription Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the "Agreements."

2.3 Investor represents and acknowledges that the no placement agent or other person is owed any commissions or other amounts related to the sale of the Shares to the Investor.

2.4 The Company confirms that neither it nor any other person acting on its behalf has provided the Investor or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, nonpublic information, except as will be disclosed in the Prospectus and/or in the Company's Form 8-K to be filed with the Commission in connection with the Offering. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company.

3. Closings and Delivery of the Shares and Funds.

3.1 Closing.  The completion of the purchase and sale of the Shares (the "Closing") shall occur at a place and time (the "Closing Date") as agreed upon by the Company and the Investors. At the Closing, the Company shall deliver the Company's transfer agent a copy of this Agreement and instructions to issue a certificate or electronically through DWAC evidencing the Shares set forth on the Signature Page registered in the name of the Investor or, if so indicated on the Investor Questionnaire attached hereto as Exhibit A, in the name of a nominee designated by the Investor.

3.2 Conditions to the Obligations of the Parties.

(a) Conditions to the Company's Obligations. The Company's obligation to issue and sell the Shares to the Investor shall be subject to: (i) the receipt by the Company of the purchase price for the Shares being purchased hereunder as set forth on the Signature Page and (ii) the accuracy of the representations and warranties made by the Investor and the fulfillment of those undertakings of the Investor to be fulfilled prior to the Closing Date.

(b) Conditions to the Investor's Obligations. The Investor's obligation to purchase the Shares will be subject to the accuracy of the representations and warranties made by the Company and the fulfillment of those undertakings of the Company to be fulfilled prior to the Closing Date. The Investor's obligations are expressly not conditioned on the purchase by any or all of the Other Investors of the Shares that they have agreed to purchase from the Company.

3.3 Delivery of Funds.  Payment for the Shares shall be made as follows:

(a) Cash Settlement.  Investor shall pay via direct wire transfer an amount equal to the aggregate purchase price for the Shares being purchased by the Investor to the following account designated by the Company:

[To be separately provided to the Investor]

3.5 Delivery of Shares.

(a) Cash Settlement:  If the Investor elects to have a cash settlement, the Investor shall wire or provide other immediately available funds to the Company and the Company shall deliver a copy of the Agreement to the transfer agent and instructions regarding the issuance of a certificate or electronically through DWAC to the Investor representing the Shares.

4. Representations, Warranties and Covenants of the Investor.

The Investor acknowledges, represents and warrants to, and agrees with, the Company that:

4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in securities presenting an investment decision like that involved in the purchase of the Shares, including investments in securities issued by the Company and investments in comparable companies, (b) has answered all questions on the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as of the date hereof and will be true and correct as of the Closing Date and (c) in connection with its decision to purchase the Shares set forth on the Signature Page, has received and is relying only upon the Disclosure Package and the documents incorporated by reference therein and the Offering Information.

4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by the Company that would permit an offering of the Shares, or possession or distribution of offering materials in connection with the issue of the Shares in any jurisdiction outside the United States where action for that purpose is required and (b) if the Investor is outside the United States, it will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense.

4.3 (a) The Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' and contracting parties' rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except as to the enforceability of any rights to indemnification or contribution that may be violative of the public policy underlying any law, rule or regulation (including any federal or state securities law, rule or regulation).

4.4 The Investor understands that nothing in this Agreement, the Prospectus, the Disclosure Package, the Offering Information or any other materials presented to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors and made such investigation as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares.

4.5 The Investor will maintain the confidentiality of all information acquired as a result of the transactions contemplated hereby prior to the public disclosure of that information by the Company in accordance with Section 13 of this Annex.

4.6 Investor has not engaged in any purchases or sales of the securities of the Company (including, without limitation, any Short Sales (as defined herein) involving the Company's securities). The Investor covenants that it will not engage in any purchases or sales of the securities of the Company (including Short Sales) from the time the Investor received material pricing information regarding the offering until the time that the transactions contemplated by this Agreement are publicly disclosed. The Investor agrees that it will not use any of the Shares acquired pursuant to this Agreement to cover any short position in the Common Stock if doing so would be in violation of applicable securities laws. For purposes hereof, "Short Sales" include, without limitation, all "short sales" as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sales contracts, options, puts, calls, short sales, swaps, "put equivalent positions" (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

4.7 The Investor has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the Offering and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

5. Survival of Representations, Warranties and Agreements; Third Party Beneficiary. Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the Shares being purchased and the payment therefor.

6. Notices.  All notices, requests, consents and other communications hereunder will be in writing, will be delivered (a) if within the domestic United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile or (b) if delivered from outside the United States, by International Federal Express or facsimile, and will be deemed given (i) if delivered by first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two business days after so mailed, and (iv) if delivered by email attachment or facsimile number, upon the date of transmission, and will be delivered and addressed as follows:

(a) if to the Company:

626 East 1820 North

Orem, Utah 84097

Attention: Bob Bench

Email: bobbench@nabufit.com

with a copy to:

Carman Lehnhof Israelsen, LLP

299 South Main Street, Suite 1300

Salt Lake City, Utah 84111

Attention: J. Martin Tate

Email: mtate@clilaw.com

(b) if to the Investor, at its address on the Signature Page hereto, or at such other address or addresses as may have been furnished to the Company in writing.

7. Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and Investor.

8. Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be part of this Agreement.

9. Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

10. Governing Law.   This Agreement will be governed by, and construed in accordance with, the internal laws of the State of Delaware, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

11. Counterparts. This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. The Company and the Investor acknowledge and agree that the Company shall deliver its counterpart to the Investor along with the Prospectus (or the filing by the Company of an electronic version thereof with the Commission).

12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor's receipt of the Company's signed counterpart to this Agreement, together with the Prospectus (or the filing by the Company of an electronic version thereof with the Commission), shall constitute written confirmation of the Company's sale of the Shares to such Investor.

13. Press Release; Disclosure. The Company and the Investor agree that the Company shall (a) prior to the opening of the financial markets in New York City on July 1, 2016 issue a press release announcing the Offering and disclosing all material information, including, without limitation, the material terms, regarding the Offering, not previously disclosed, permitted under existing SEC rules applicable to press releases, and (b) as promptly as practicable on July 1, 2016 file a current report on Form 8-K with the Shares and Exchange Commission. From and after the issuance of such press release, the Company represents to the Investor that it shall have publicly disclosed all material, non-public information delivered to the Investor by the Company or any of its subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by this Agreement. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, agents, employees or affiliates on the one hand, and the Investor or any of their affiliates on the other hand, shall terminate. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, which shall be disclosed pursuant to the press release required above, the Company covenants and agrees that neither it, nor any other person acting on its behalf will provide Investor or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto the Investor shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. To the extent that the Company delivers any material, non-public information to an Investor without the Investor's consent, the Company hereby covenants and agrees that the Investor shall not have any duty of confidentiality to the Company, any of its subsidiaries, or any of their respective officers, directors, agents, employees or affiliates, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Investor shall remain subject to applicable law. To the extent that any notice provided pursuant to this Agreement constitutes, or contains, material, non-public information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K. The Company understands and confirms that the Investor shall be relying on the provisions of this Section 13 in effecting transactions in securities of the Company.

14. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investor that:

14.1 The Registration Statement and any prospectus included therein, including the Prospectus and any supplement thereto, complies in all material respects with the requirements of the Exchange Act and the rules and regulations of the Shares and Exchange Commission (the "Commission") promulgated thereunder and all other applicable laws and regulations. At the time the Registration Statement and any amendments thereto becomes effective (or became effective, as applicable), at the date of this Agreement and at each deemed effective date thereof pursuant to Rule 430B(f)(2) of the Shares Act, the Registration Statement and any amendments thereto complied and will comply in all material respects with the requirements of the Shares Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, complied, and will comply, in all material respects with the requirements of the Shares Act and did not, and will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

14.2 As of their respective dates, all reports, schedules, forms, statements and other documents filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act during the two (2) years prior to the date hereof (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the "SEC Documents") complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. The Company is not currently contemplating to amend or restate any of the financial statements (including without limitation, any notes or any letter of the independent accountants of the Company with respect thereto) included in the SEC Documents (the "Financial Statements"), nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with generally accepted accounting principles and the rules and regulations of the Commission. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

15. Equal Treatment of Purchasers. No consideration (including any modification of any subscription agreement executed pursuant to the Offering each a "Transaction Document")) shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also offered to the each investor party to the Offering pursuant to this Agreement or other Subscription Agreements, including the Investor. For clarification purposes, this provision constitutes a separate right granted to the Investor by the Company and negotiated separately by the Investor, and is intended for the Company to treat the investors party to the Offering as a class and shall not in any way be construed as any of the investors party to the Offering acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.

16. USA PATRIOT Act.  To comply with applicable laws, rules and regulations designed to combat money laundering or terrorism, Investor shall provide the information on Exhibit B hereto.

EXHIBIT A

NABUFIT GLOBAL, INC.

INVESTOR QUESTIONNAIRE

Pursuant to Section 3 of Annex I to the Agreement, please provide us with the following information:

	
1.

	
The exact name that your Shares are to be registered in. You may use a nominee name if appropriate:

	
 

	
 

	
 

	
 

	
2.

	
The relationship between the Investor and the registered holder listed in response to item 1 above:

	
 

	
 

	
 

	
 

	
3.

	
The mailing address of the registered holder listed in response to item 1 above:

 

	
 

	
 

	
 

	
 

	
4.

	The Social Security Number or Tax Identification Number of the registered holder listed in the response to item 1 above:

 

	
 

	
 

	
 

	
 

EXHIBIT B

USA PATRIOT ACT COMPLIANCE

 

	
i.

	
Name of the bank from which the Investor's payment to the Company is being wired (the "Wiring Bank"):

	
 

	
 

	
 

	
 

	
ii.

	
Is the Wiring Bank located in the United States or another "FATF Country"1?

	
 

	
☐ Yes

	 	☐ No 
	
 

	
 

	
iii.

	
If the Investor answered "Yes," is the Investor a customer of the Wiring Bank?

	
 

	
☐ Yes

	
 

	
☐ No

	 	 

  

If the Investor answered "No" to questions 2 or 3 above, the Investor may be required, if the Investor is an individual, to produce a copy of a passport or identification card, together with any evidence of the Investor address, such as a utility bill or bank statement, and date of birth.  If the Investor is an entity, the Investor may be required to produce a certified copy of the Investor's certificate of incorporation, articles of association (or the equivalent) or certificate of formation or limited partnership (or the equivalent), and the names, occupations, dates of birth and residential and business addresses of all directors.

1 As of the date hereof, countries that are members of the Financial Action Task Force on Money Laundering (each an "FATF Country") are:  Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hong Kong, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, Kingdom of the Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom, and the United States.  The list of FATF Countries may be expanded to include future FATF members and FATF compliant countries, as appropriate.Exhibit 10.3

 

 

	
Thomas Renaud, Agent

Daniel Renaud, Agent

Fredric Obsbaum, Manager

	
Arrowhead Capital Advisors,

a division of Trump Securities, LLC

39 Broadway, Suite 3300

New York, NY 10006, United States

Tel:  +1 212 509 7800

August 19, 2016

NABUFIT Global, Inc.

626 East 1820 North, Orem, UT, 84097, United States.

Brian Mertz; CEO

Phone: +4523903300  Denmark

Email: bm@nabufit.com

Bob Bench; CFO

Phone: 801-362-2115

Email: bobbench@nabufit.com

 

	Attn:	Mr. Brian Palm Svaneeng Mertz - Chief Executive Officer

Mr. Robert Bench – Chief Financial Officer

Private Placement and Advisory

Dear Mr. Mertz and Mr. Bench,

This letter (the "Agreement") will confirm our understanding that NABUFIT Global, Inc. (the "Company") has engaged Arrowhead Capital Advisors, a division of Trump Securities, LLC ("ACA" or "Advisor") to act as the Company's non-exclusive placement agent in connection with a Transaction as defined below. The specific terms and conditions of the Transaction shall be determined by good faith negotiations between the parties in the Transaction. References herein to the "Company" shall be deemed to include without limitation, any entity in existence or formed, that the Company, whichever the case may be, may form or utilize to effect the Transaction.

Transaction.  For purposes of this agreement, the term "Transaction" (the "Transaction") shall include, without limitation, any transaction or series or combination of related transactions whereby, directly or indirectly, an interest or equity in, a loan to, a royalty, an off-take agreement, or a licensing agreement with the Company and/or its subsidiaries or any amount of their respective assets, is transferred for consideration, including, without limitation, by means of a sale or exchange of capital stock or assets, a merger or consolidation, a tender or exchange offer, a leveraged buy-out, a minority investment, a spin-off or a split-off, the formation of a joint venture or partnership, or any similar transaction, or any revolving credit facility.

Section 1.   Scope of Engagement and Services.  In connection with this engagement, ACA shall, as appropriate:

	
(a)

	
familiarize itself to the extent appropriate and feasible with the business, operations, properties, financial condition and prospects of the Company in order to, among other things, analyze the potential contributions of such business, operations and facilities to the Company's future operating results, it being understood that Advisor shall be entitled, in the course of such familiarization, to rely upon publicly available information and such other information as may be supplied by the Company, without independent investigation;

	
(b)

	
advise and assist the Company in negotiating the terms and conditions of the above defined or other transaction;

	
(c)

	
introduce the Company to business partners ("Introduced Parties"); this Agreement also covers indirect introductions from Introduced Parties – that is, if an Introduced Party introduces the Company to a third party, then this third party is also deemed an Introduced Party; a list of Introduced Parties will be appended hereto as Annex B and incorporated herein and will be updated from time to time as appropriate;

	
(d)

	
advise and assist management in preparing for presentations to investors, lenders and/or other financial sources, including the development of the best strategy for demonstrating the experience of management and the scope of such experience;

	
(e)

	
perform such other financial advisory services as ACA and the Company may from time to time agree upon.

Section 2.   Compensation.

	
(a)

	
Upon the execution of this Agreement, the Company shall pay to Trump Securities a due diligence cash fee of US$10,000 ("fifteen thousand US dollars").

	
(b)

	
In the event a Transaction is consummated with any Introduced Parties, the Company will also pay to Trump Securities an aggregate transaction fee (the "Transaction Fee") as stated below, consisting of a Cash Fee. All such fees shall be immediately paid by the Company to Trump Securities at the closing of the Transaction, however, if such Transaction occurs through multiple closings, then pro rata portion of such fees shall be paid upon each closing:

	
i.

	
Cash Fee.  The Company shall pay to Trump Securities an aggregate cash fee equal to ten percent (10%) of the aggregate amount of the Transaction.

	
(c)

	
If the Transaction is not consummated prior to the expiration or termination of this agreement, Trump Securities shall be entitled to the full Transaction Fee set forth in Section 2(b) with respect to any Transaction consummated with any Introduced Parties within eighteen (18) months following the expiration or termination of this Agreement. (the "Tail Period")

Section 3.   Indemnification.The Company agrees to indemnify and defend ACA in accordance with the provisions of Annex A hereto, which is incorporated by reference and made a part hereof.

Section 4.   Expenses.The Company shall reimburse ACA for all of its Company-pre-approved, actual and out-of-pocket expenses, including but not limited to reasonable and documented travel, legal fees and other expenses, incurred in connection with the Transaction, whether or not the Transaction is completed, subject to presentation of appropriate documentation evidencing such out-of-pocket expenses. ACA will not bear any of the Company's legal, accounting, printing or other expenses in connection with any transaction considered or consummated hereby. It also is understood that ACA will not be responsible for any fees or commissions payable to any finder or to any other financial or other advisor utilized or retained by the Company.

Section 5.   ACA's and the Company's Relationships with Others. The Company acknowledges that ACA and its affiliates are in the business of providing investment banking, financial advisory and consulting services to others and agrees that the provision of such services shall not constitute a breach hereof of any duty owed to the Company by virtue of this Agreement.  Nothing contained herein, other than ACA's obligations relating to the Company's Confidential Material as provided in Section 6 hereof, shall be construed to limit or restrict ACA or its respective affiliates in conducting such businesses with respect to others or in rendering such services to others.

2

Section 6.   Confidential Information. In connection with the rendering of services hereunder, ACA has been or will be furnished with certain confidential information of the Company including, but not limited to, financial statements and information, cost and expense data, scientific data, intellectual property, trade secrets, business strategies, marketing and customer data, and such other information not generally available from public or published information sources. Such information shall be deemed "Confidential Material", shall be used solely in connection with the provision of services contemplated hereby, and shall not be disclosed by ACA without the prior written consent of the Company.  In the event ACA is required by applicable law or legal process to disclose any of the Confidential Material, ACA will deliver to the Company prompt notice of such requirement, if legally permissible, (by fax or overnight courier promptly following ACA's knowledge or determination of such requirement) prior to such disclosure so the Company may seek an appropriate protective order and/or waive compliance of this provision. If, in the absence of a protective order (because the Company elected to not seek such an order or it was denied by a court of competent jurisdiction) or receipt of written waiver, ACA is nonetheless, in the written opinion of its counsel, compelled to disclose any Confidential Material, ACA may do so without liability hereunder.

Section 7.   Limitation Upon the Use of Advice and Services.

	(a)	No person or entity, other than the Company and its affiliates and subsidiaries (including its directors, officers and employees), shall be entitled to make use of, or rely upon any advice of ACA to be given hereunder, and the Company shall not transmit such advice to, or encourage or facilitate the use or reliance upon such advice by others without the prior written consent of ACA.

	
(b)

	
The Company hereby acknowledges that ACA, for services rendered as contemplated by this Agreement, does not make any commitment whatsoever to make a market in any of the Company's securities on any stock exchange or in any electronic marketplace.

	
(c)

	
Use of ACA's name in annual reports or any other report of the Company or releases by the Company requires the prior written approval of ACA unless the Company is required by law to include ACA's name in such annual reports, other report or release of the Company, in which event the Company shall furnish to ACA copies of such annual reports or other reports or releases using ACA's names in advance of publication by the Company.

Section 8.   Public Announcements.  The Company agrees that ACA may place announcements or advertisements or otherwise publicize ACA's role hereunder subject to an advanced approval in writing, by the Company, of such publication and to any applicable law, including the US securities regulations.  The Company further agrees to include reference to ACA and ACA's role in the Transaction in the press releases regarding the Transaction (the "Press Releases").  ACA shall have the right to review and approve the Press Releases prior to publication, ACA's approval not unreasonably withheld.

Section 9.   No Finders or Other Brokers.  The Company represents that this agreement does not conflict with any other finder or broker agreement entered into by Company, and that, without limitation, if another person or entity is entitled to payment by Company of a finder's fee or any type of brokerage commission in connection with any Transactions contemplated by this Agreement as a result of any agreement or understanding with the Company, this will not reduce Company's obligations to ACA hereunder.

3

Section 10.   Information; Cooperation.  The Company will cooperate with and will furnish ACA with all reasonable information and data concerning the Company and the Transaction, which ACA deems appropriate and will provide ACA with reasonable access to the Company's officers, directors, employees, independent accountants and legal counsel. The Company represents that all information and any disclosure materials made available to ACA for distribution to investors will be complete and correct in all material respects and will not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which such statements are made. The Company further represents and warrants that to the extent any projections are furnished, such projections will have been prepared in good faith and will be based upon assumptions, which, in light of the circumstances under which they are made, are reasonable. ACA shall not deliver to any prospective investors any information concerning the Company, unless the Company has previously consented to the distribution of such information.

 

Section 11.   Miscellaneous.

	(a)	Any notice or communication between the parties hereto shall be sufficiently given if sent by certified or registered mail, postage prepaid, or faxed and confirmed if to the Company, addressed to it at its address as stated on the first page of this Agreement, or if to ACA, addressed to them at: 39 Broadway, Suite 3300, New York, NY 10006, United States. Such notice or other communication shall be deemed to be given on the date of receipt.

	
(b)

	
This Agreement embodies the entire agreement and understanding between the Company and ACA and supersedes any and all negotiations, prior discussions and preliminary and prior agreements and understandings that ACA may have had with the Company related to the subject matter of advisory on private placements, and may be modified only by a written instrument duly executed by each party.  This Agreement shall inure to the benefit of and be binding upon the successors, assigns and personal representatives of each of the parties hereto. This Agreement has been duly authorized, executed and delivered by and on behalf of the Company and ACA.

	
(c)

	
This Agreement shall be deemed to have been made and delivered in New York City and shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York without regard to principles of conflicts of law thereof.  Any and all disputes, controversies or claims arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be finally and exclusively resolved by arbitration in accordance with the Rules of FINRA as at present in force. The arbitration shall take place in New York City, the State of New York. The parties hereby submit themselves to the exclusive jurisdiction of the arbitration tribunal in the City of New York, the State of New York under the auspices of FINRA. To the extent permitted by law, the award of the arbitrators may include, without limitation, one or more of the following: a monetary award, a declaration of rights, an order of specific performance, an injunction, reformation of the contract. The decision of the arbitrators shall be final and binding upon the parties hereto, and judgment on the award may be entered in any court having jurisdiction over the subject matter thereof. Each party to the arbitration shall bear its own expenses of the arbitration (including without limitation reasonable fees and expenses of counsel, experts and consultants).

	
(d)

	
There is no relationship of partnership, agency, employment, franchise or joint venture between the parties.  No party has the authority to bind the other or incur any obligation on the other's behalf.

4

	
(e)

	
The Company hereby acknowledges that ACA is not a fiduciary of the Company.  ACA makes no representations or warranties regarding the Company's ability to secure financing, whether now or in the future.

	
(f)

	
This Agreement and the rights hereunder may not be assigned by either party (except by operation of law).

	
(g)

	
Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction.  If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only as broad as is enforceable.

Section 12. Termination.  The term (the "Term") of ACA's engagement hereunder shall commence on the date hereof and shall end upon termination by either of the parties. This Agreement can be terminated as follows: (i) seven (7) days after receipt of written notice of termination from either party for any reason.

In the event of any termination of this Agreement prior to the expiration of the Term, this Agreement shall become null and void, except for indemnity obligations of all parties hereunder, reimbursement for Placement Agent expenses incurred up to the date of such termination in accordance with Section 4 hereunder and fees that are or may become due to ACA under Section 2 hereunder.

In addition, in the event this Agreement shall be terminated in accordance with the provisions of this Section 12 or upon expiration of this Agreement, the sections headed "Confidential Information," "Indemnification," "Miscellaneous," "Expenses," and the "Tail Period" provisions set forth under Section 2 will survive.

Signature page follows

5

We are delighted to accept this engagement and look forward to working with you on this assignment.  Please confirm that the foregoing is in accordance with your understanding by signing and returning to us one copy of this enclosed duplicate of this agreement.

Very truly yours,

ARROWHEAD CAPITAL ADVISORS, A DIVISION OF TRUMP SECURITIES, LLC

Agreed to and Accepted as of the date above

 

	
Representing ACA / TRUMP:

	
 

	
 

	
By: 

	
/s/ Fredric Obsbaum

	
 

	
Fredric Obsbaum

	
 

	
Manager

	
 

	
 

	
By: 

	 /s/ Thomas Renaud
	
 

	
Thomas Renaud

	
 

	
Agent

	
 

	
 

	
By: 

	/s/ Daniel Renaud 
	 	
Daniel Renaud 

	 	Agent 
	 	 

 

 

	
NABUFIT GLOBAL, INC.

	
 

	
 

	
By: 

	
 

	
 

	Brian Palm Svaneeng Mertz
	
 

	
Chief Executive Officer

	
 

	
 

	
By: 

	 /s/ Robert Bench
	
 

	
Robert Bench

	
 

	
Chief Financial Officer

	
 

	
 

6

 

ANNEX A

INDEMNIFICATION

The Company agrees to indemnify and defend and hold harmless ACA and its affiliates and their respective officers, directors, employees, agents and controlling persons (ACA and each such person being an "Indemnified Party"), from and against any losses, claims, damages and liabilities, joint or several, to which such Indemnified Party may become subject under any applicable law, or otherwise, which relate to or arise in any manner out of any transaction, financing, or any other matter (collectively, the "Matters") contemplated by the engagement letter of which this Annex A forms a part  and the performance by ACA of the services contemplated thereby, and will promptly reimburse each Indemnified Party for all reasonable expenses (including reasonable fees and expenses of legal counsel) as incurred in connection with the investigation of, preparation for or defense of any pending or threatened claim or any action or proceeding arising therefrom, whether or not such Indemnified Party is a party and whether or not such claim, action or proceeding is initiated or brought by or on behalf of the Company. Notwithstanding the foregoing, the Company shall not be liable under the foregoing to the extent that any loss, claim, damage, liability or expense is found in a final judgment by a court of competent jurisdiction to have resulted solely from ACA's bad faith or gross negligence.

If the indemnification of an Indemnified Party provided for this letter agreement is for any reason held unenforceable, although otherwise applicable in accordance with its terms, the Company agrees to contribute to the losses, claims, damages and liabilities for which such indemnification is held unenforceable (i) in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and ACA's, on the other hand, of any Matter (whether or not the Matter is consummated) or (ii) if (but only if) the allocation provided for in clause (i) is for any reason held unenforceable, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and ACA, on the other hand, as well as any other relevant equitable considerations. The Company agrees that for the purposes of this paragraph the relative benefits to the Company and ACA of any contemplated Matter (whether or not such Matter is consummated) shall be deemed to be in the same proportion that the total value paid or received or to be paid or received by the Company as a result of or in connection with any Matter, bears to the fees paid or to be paid to ACA under the engagement letter; provided, however, that, to the extent permitted by applicable law, in no event shall the Indemnified Parties be required to contribute an aggregate amount in excess of the aggregate fees actually paid to ACA under the engagement letter of which this Annex A is a part.

Promptly after receipt by ACA or any other Indemnified Party of any notice of any proceeding, or the commencement of any legal action or proceeding in respect of which indemnity may be sought against the Company, ACA or such other Indemnified Party shall notify the Company promptly in writing of the receipt of any such notice or commencement of such an action or proceeding.  In the event the Company shall be obligated under this Indemnification Annex to indemnify ACA and/or such other Indemnified Party, the Company may assume and control all aspects of the defense of such proceeding, including, inter alia, selection of counsel and other professionals (which counsel and professionals shall be reasonably acceptable to ACA) and, subject to the next paragraph, settlement; provided, however, that the Indemnified Parties shall have the right to retain separate counsel, but the fees and expenses of such counsel shall be at the expense of the Indemnified Parties, unless (i) the employment of such counsel has been specifically authorized in writing by the Company, (ii) the Company has failed to assume the defense and employ reasonably acceptable counsel as required above, or (iii) the named parties to any such action (including any impleaded parties) include both (a) the Indemnified Parties and (b) the Company, and the Indemnified Parties shall have reasonably determined that the defenses available to them are not available to the Company and/or may not be consistent with the best interests of the Company or the Indemnified Parties (in which case the Company shall not have the right to assume the defense of such action on behalf of the Indemnified Parties); it being understood, however, that the Company shall not, in connection with any one such action or separate, substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys for the Indemnified Parties, which firm shall be designated in writing by ACA.

7

The Company agrees that it will not, without the prior written consent of ACA, settle, compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding in respect of which indemnification may be sought hereunder (whether or not ACA or any other Indemnified Party is an actual or potential party to such claim, action or proceeding), unless such settlement, compromise or consent includes an unconditional release of ACA and each other Indemnified Party hereunder from all liability arising out of such claim, action or proceeding.

If ACA or any other Indemnified Party is requested or required to appear as a witness in any action brought by or on behalf of or against the Company in which such party is not named as a defendant, the Company will reimburse ACA for all reasonable expenses incurred in connection with such party's appearing and preparing to appear as such a witness, including, without limitation, the fees and disbursements of its legal counsel.

The provisions of this Annex A shall continue to apply and shall remain in full force and effect regardless of any modification or termination of the engagement or engagement letter of which this Annex A is a part or the completion of ACA's services thereunder.

8

ANNEX B

INTRODUCED PARTIES

As of  August 19th, 2016 (to be updated periodically)

1.

2.

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]